DIA: Your Partner in Life Sciences Training and Development

DIA/Tufts CSDD Research: AI Saving Time in Drug Development

DIA and the Tufts Center for the Study of Drug Development (Tufts CSDD), in collaboration with 16 biopharmaceutical companies and CROs, conducted a study to map current use of and experience with artificial intelligence (AI) and machine learning (ML), and their ability to reduce time across activities, in the drug development lifecycle. “We benchmarked various applications of AI and ML to 36 activities within clinical operations and development. We focused on design and planning, execution, and regulatory submissions, and looked at time reductions from investments in the use of AI and ML in a typical development program,” explains Tufts CSDD Director of Sponsored Research Mary Jo Lamberti in this interview with Stephanie Rosner (Scientific Program Manager for AI, DIA). “We expect to see higher levels of full implementation across all activities over the next few years.”

DIA: Your Partner in Life Sciences Training and Development

This  podcast by the Drug Information Association (DIA) highlights the significant benefits of investing in professional development programs for employees in the life sciences industry. They emphasizes how training and development initiatives accelerate product development, improve employee retention, and foster a strong workplace culture. It showcases DIA’s commitment to providing comprehensive learning solutions that address specific industry needs and equip professionals with the skills and knowledge necessary for success.   Reach out to business.solutions@diaglobal.org [business.solutions@diaglobal.org] for more information.    Audio generated by NotebookLM, OpenAI, October 29, 2024, https://notebooklm.google/ [https://notebooklm.google/]

DIA: Going Beyond the Traditional Definition of Drug Development

In this DIA 60th anniversary interview, former Board President Ling Su shares his thoughts on the two most important aspects of DIA’s future for the next generation of members.

GPP Experts Explain Authorship Algorithm

Good Publication Practice (GPP) experts explain the authorship algorithm designed to weigh each author's contribution relative to other authors' contributions in a study, and to define appropriate ways to establish the authorship byline.

"Dossier in the Cloud" Democratizing Global Access

Accumulus Synergy CEO Francisco Nogueira shares expectations for the outcomes of a post-approval changes pilot led by Roche which utilizes the Accumulus platform and follows WHO principles of good regulatory reliance practices.